about
Response variability to P2Y12 receptor inhibitors: expectations and realityThe acute and short-time effect of supplementation with the combination of n-3 fatty acids and acetylsalicylic acid on platelet function and plasma lipidsClopidogrel: background information and use in clinical practiceBleeding complications after treatment with antithrombotic agents after acute coronary syndromeDo the Behring Coagulation Timer and the Platelet Function Analyzer-100 identify the same patients as being aspirin non-responders?Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure.Marine n-3 polyunsaturated fatty acids and coronary heart disease. Part I. Background, epidemiology, animal data, effects on risk factors and safety.Investigation of platelet function and platelet disorders using flow cytometry.Flow cytometric analysis of platelet cyclooxygenase-1 and -2 and surface glycoproteins in patients with immune thrombocytopenia and healthy individuals.Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries.Universal definition of myocardial infarction.Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study.Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European SocNew oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of AGenetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1.2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).Calprotectin and platelet aggregation in patients with stable coronary artery diseaseDeterminants of reduced antiplatelet effect of aspirin in patients with stable coronary artery diseaseThe Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with AspirinPre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction.Anticoagulants in heart disease: current status and perspectives.European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituteEuropean guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by repGastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapyIncidence of bleeding in 'real-life' acute coronary syndrome patients treated with antithrombotic therapy.Stent for Life Initiative: where are we standing and where are we going?Update on oral antiplatelet therapy: principles, problems and promises.Platelet turnover in stable coronary artery disease - influence of thrombopoietin and low-grade inflammation.Status of Stent for Life Initiative across Europe.Antiplatelet agents for the treatment and prevention of atherothrombosis.Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines.Pharmacogenetics of the antiplatelet effect of aspirin.Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?How can we optimize the processes of care for acute coronary syndromes to improve outcomes?Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial.Impact of arterial access site on outcomes after primary percutaneous coronary intervention: prespecified subgroup analysis from the EUROMAX trial.Reduced Effect of Aspirin and Clopidogrel Following Hybrid Coronary Revascularization.
P50
Q26999243-A833856E-7471-4AC0-A4F1-8B891DC47B00Q28193070-40D7C5A7-E5B2-4701-B47C-27EE5B940166Q28196309-1EE3312F-B1CE-4665-A277-928FA7A86E9CQ28200623-CC6BB738-5CD6-4C40-9D35-A1C74FC6275FQ28218887-BBA09435-5A1B-4E41-BF77-53A0483ACAD5Q31126985-34B8F1CC-C0B2-4BD9-832E-5F079B7924F5Q33210335-D57C2AD7-430C-4D17-B78D-99032D69D728Q33422250-8C4499FD-10CA-47C8-9FC1-3CD5B8D1E358Q33435826-6DC6CEDC-22DD-4F34-9A1B-04ACF6759C58Q33535020-9879C5A2-4DBE-4379-8E72-75149A54FE55Q33788973-9AD75188-3D70-40D7-97E8-473826A9A992Q34007701-1EB4A57F-8308-4CED-8F1E-F85D6D74DFE3Q34055438-260AAC16-5741-4F75-A4BA-7CE56406297EQ34092420-760A03FF-F24B-4E23-A8DB-45FC5C32B14CQ34267825-11ED9D80-07A4-42C0-9901-1A125C4E5CBBQ34431980-80E9E205-2FC5-4A23-BB95-4B550D9D56E2Q34435298-10EF699E-C455-4492-BF0B-DF99FE86A29CQ34636529-0634E23D-89E0-4C2F-BFD1-6CFC4CBFDE7EQ35603084-8E26A371-F625-465D-8675-86133452A9B2Q35620590-D8F04DDD-215F-4092-B9B9-D70181A0A78FQ35684231-3009CFEC-B9DE-4641-977F-571AD8277078Q36213440-F2F256B9-BF24-49FE-A3C7-2CE28D3FD1B4Q36787643-41675EF8-F897-4192-BED4-83A0461F60E7Q36921887-FE7779F3-2578-4434-918F-BBB25503310EQ36921892-C230C65E-F22A-4BC9-A7AA-41A905629F3FQ36921947-EABC06E3-4055-4F62-9EE3-889C62BDAFCDQ37073391-6D75C072-8ED3-4901-9384-1403FA460F85Q37140949-85A5F912-2823-4213-B6E0-2CDABCFC4038Q37486605-465E25D7-F618-407B-87F5-82A6F587FA15Q37499510-C521B533-FC76-446A-8EBC-8FE57405BA09Q37947402-58252AF1-05D1-43BE-AA88-94907D854888Q37948506-B1BEFB5C-6ABF-42AE-A04E-68C820591BBDQ37998114-482B3447-57B2-407F-AED1-9C551E7D2F10Q38020866-5182C886-DD42-4D40-8AB4-1E9C85AA9054Q38273902-A8FC3746-B602-4ACC-A3FE-11482A65012CQ38273904-5F733E8A-9087-4E1F-AD9D-FD2289CDBEA3Q38390171-2E042EE5-DDDF-45E3-AF45-77A96E3B9582Q38392662-63CC3773-69FB-4B67-9B9C-80FD621F38E1Q38410168-439311DD-E5D7-4163-BA47-0BA7F4C98233Q38415209-EB910B0E-03BA-4842-8BC2-E9FBA7115F41
P50
name
Steen Dalby Kristensen
@en
type
label
Steen Dalby Kristensen
@en
prefLabel
Steen Dalby Kristensen
@en